Scribe Therapeutics Inc. (SCTX) Key Metrics
SCTX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $380.1M
- Enterprise value
- $502.5M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 11.4
- Price / book
- —
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
SCTX key metrics, 2024–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSCTX returns How much profit the business earns on the capital it uses.
Return on assets+16.2 pts
−21.2%
2025 · hover or tap a bar for each year
20242025
Free cash flow margin+79.1 pts
−90.8%
2025 · hover or tap a bar for each year
20242025
Asset turnover+131.7%
0.50
2025 · hover or tap a bar for each year
20242025
SCTX per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+86.7%
$2.91
2025 · hover or tap a bar for each year
20242025
Earnings per share
−$1.24
2025 · hover or tap a bar for each year
20242025
Free cash flow per share
−$2.64
2025 · hover or tap a bar for each year
20242025
Book value per share
−$8.16
2025 · hover or tap a bar for each year
20242025
Shares outstanding0.0%
17.6M
2025 · hover or tap a bar for each year
20242025
SCTX financial health Debt, liquidity and how easily interest is covered.
Net debt−$34.7M
−$12.8M
2025 · hover or tap a bar for each year
20242025
Current ratio−69.2%
0.97
2025 · hover or tap a bar for each year
20242025
Interest coverage
-10.9
2025 · hover or tap a bar for each year
20242025
SCTX efficiency & capital use Working capital cycle and where the cash goes.
Capex / revenue−2.4 pts
2.5%
2025 · hover or tap a bar for each year
20242025
SCTX returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SCTX debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SCTX key metrics
2024–2025| 2025 | 2024 | |
|---|---|---|
| Per share | ||
| Revenue per share | $2.91 | $1.56 |
| Earnings per share | −$1.24 | −$2.72 |
| Operating cash flow per share | −$2.57 | −$2.57 |
| Free cash flow per share | −$2.64 | −$2.65 |
| Cash per share | $0.73 | $0.72 |
| Book value per share | −$8.16 | −$7.16 |
| Tangible book value per share | −$8.16 | −$7.16 |
| Capex per share | $0.07 | $0.08 |
| Debt per share | — | $1.96 |
| Shares outstanding | 17.6M | 17.6M |
| Change in shares outstanding | 0.0% | — |
| Returns & profitability | ||
| Return on assets (ROA) | −21.2% | −37.3% |
| Return on tangible assets | −27.9% | −37.3% |
| Free cash flow margin | −90.8% | −169.9% |
| Financial health | ||
| Total debt | — | $34.5M |
| Cash & short-term investments | $12.8M | $12.6M |
| Net debt | −$12.8M | $21.9M |
| Debt / assets | — | 0.27 |
| Current ratio | 0.97 | 3.15 |
| Quick ratio | 0.97 | 3.15 |
| Interest coverage | -10.9 | -18.0 |
| Working capital | −$2.1M | $75.4M |
| Invested capital | −$156.2M | −$104.0M |
| Tangible asset value | −$143.4M | −$125.9M |
| Net current asset value | −$154.7M | −$143.5M |
| Graham net-net per share | −$11.88 | −$13.72 |
| Capital allocation | ||
| Capex / revenue | 2.5% | 4.9% |
| Capex / depreciation | 0.41 | 0.47 |
| Stock-based compensation / revenue | 8.1% | 10.4% |
| R&D / revenue | 118.8% | 208.2% |
| SG&A / revenue | 32.1% | 48.0% |
| Efficiency | ||
| Asset turnover | 0.50 | 0.21 |
| Average payables | $4.2M | $3.8M |
| Intangibles / total assets | 0.0% | 0.0% |
Computed from SCTX's annual financial statements (latest annual report filed —) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SCTX valuation and financial ratios
See the SCTX income statement, the SCTX chart for price history, or the SCTX stock overview for the latest quote and news.
SCTX key metrics FAQ
What is Scribe Therapeutics's current ratio?
Scribe Therapeutics's current ratio was 0.97 at the end of fiscal 2025: current assets were 0.97 times current liabilities.